TNF and Cowden disease: The evidence base for the efficacy of anti-TNFα agents in oral CD specifically is largely limited to case reports where an anti-TNFα has been employed primarily for management of coexistant intestinal disease, but several studies have demonstrated good efficacy of infliximab and adalimumab for other extraintestinal manifestations of CD (8).